At its meeting on 18 July 2022 the Transparency Council adopted Opinion No. 117/2022 on the active substance ipratropii bromidum for the following off-label indications: cystic fibrosis; bronchopulmonary dysplasia; ciliary dyskinesia; acute bronchitis in case of airway obstruction.
Publication in Public Information Bulletin (BIP)